Mumbai ,Maharashtra ,India, February 2026 — Abbott Diabetes Care has appointed Mumta Nayyar as General Manager – India, strengthening its leadership as the company accelerates innovation in continuous glucose monitoring (CGM) and connected diabetes management solutions.
In her new role, Mumta will oversee strategic growth, commercial expansion, and market development across India — one of the world’s largest diabetes care markets. Her mandate includes expanding access to next-generation monitoring systems, strengthening healthcare partnerships, and driving sustainable, patient-centric growth aligned with Abbott’s digital health ecosystem strategy.
Prior to this appointment, Mumta held multiple leadership roles at Edwards Lifesciences, where she most recently served as Director – Surgical Structural Heart, Greater India. Over an extensive tenure spanning sales, marketing, and product leadership roles, she contributed to market expansion, portfolio growth, and team development across complex medical technology segments.
Earlier, she served as Regional Sales Manager at Medtronic, driving regional commercial strategy and sales performance. She also held product and sales leadership roles at Edwards Lifesciences earlier in her career, and began her professional journey at Ranbaxy Labs Ltd., building foundational experience in the pharmaceutical sector.
With over two decades of leadership experience across medical devices, structural heart technologies, and healthcare commercialization, Mumta Nayyar brings strong expertise in market expansion, innovation-led growth, and strategic execution. Her appointment aligns with Abbott’s broader commitment to improving diabetes outcomes through digital integration, accessibility, and scalable healthcare solutions across India and the wider APAC region.
About Abbott Diabetes Care
Abbott Diabetes Care, a division of Abbott, is a global healthcare leader advancing life-changing technologies across diagnostics, medical devices, nutrition, and branded generic medicines. With operations in more than 160 countries, Abbott is at the forefront of continuous glucose monitoring (CGM) innovation, enabling patients and clinicians to make informed, real-time health decisions through connected and data-driven solutions.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
